Relationship between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer

JAMA

Volumn 289, Issue 24, 2003, Pages 3254-3263

  Li, Christopher I ^a,b   Malone, Kathleen E ^a,b   Porter, Peggy L ^a,c   Weiss, Noel S ^a,b   Tang, Mei Tzu C ^a   Cushing Haugen, Kara L ^a   Daling, Janet R ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; PROGESTERONE RECEPTOR;

AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST LOBULAR CARCINOMA; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; INTRADUCTAL CARCINOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; UNITED STATES; BREAST TUMOR; CANCER REGISTRY; DRUG ADMINISTRATION; LUNG CARCINOMA; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; RISK; STATISTICAL MODEL; TIME;

AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LOGISTIC MODELS; PROGESTINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK; SEER PROGRAM; TIME FACTORS; WASHINGTON;

EID: 0038167811     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.24.3254     Document Type: Article

References (31)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047-1059.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
3. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589-1593.
4. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92:328-332.
5. Kirsh V, Kreiger N. Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control. 2002;13:583-590.
6. Chen CL, Weiss NS, Newcomb P, et al. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287:734-741.
7. Daling JR, Malone KE, Doody DR, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer. 2002;95:2455-2464.
8. Newcomer LM, Newcomb PA, Daling JR, et al. Postmenopausal hormone use and risk of breast cancer by histologic type. Am J Epidemiol. 1999;149:S79.
9. Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer. 2000;88:2570-2577.
10. Newcomb PA, Titus-Ernstoff L, Egan KM, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:593-600.
11. Stierer M, Rosen H, Weber R, et al. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer: correlation of histopathology and prognostic factors. Ann Surg. 1993;218:13-21.
12. Li CI, Anderson BO, Porter P, et al. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer. 2000;88:2561-2569.
13. Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 2003;289:1421-1424.
14. Du Toit RS, Locker AP, Ellis IO, et al. An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol. 1991;17:251-257.
15. Dixon J, Anderson T, Page D, et al. Infiltrating lobular carcinoma of the breast. Histopathology, 1982;6:149-161.
16. Potter JD, Cerhan JR, Sellers TA, et al. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many types of breast cancer are there? Cancer Epidemiol Biomarkers Prev. 1995;4:319-326.
17. Lower EE, Blau R, Gazder P, Stahl DL. The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer. Breast Cancer Res Treat. 1999;58:205-211.
18. Cobleigh MA, Norlock FE, Oleske DM, Starr A. Hormone replacement therapy and high S phase in breast cancer. JAMA. 1999;281:1528-1530.
19. National Cancer Institute. About SEER, Available at: http://www.seer.cancer.gov/. Accessibility verified May 22, 2003.
20. Fred Hutchinson Cancer Research Center. CSS Reports, Publications, & FAQs. Available at: http://css .fhcrc.org/. Accessibility verified May 22, 2003.
21. International Classification of Diseases for Oncology (ICD-O). 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
22. Breslow NE, Day NE. The Analysis of Case-Control Studies. Lyon, France: International Agency for Research on Cancer; 1980.
23. Begg CB, Gray R. Calculation of polychotomous logistic regression parameters using individualized regressions. Biometrika. 1984;71:11-18.
24. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304-313.
25. Paganini-Hill A, Ross RK. Reliability of recall of drug usage and other health-related information. Am J Epidemiol. 1982;116:114-122.
26. Goodman MT, Nomura AMY, Wilkins LR, Kolonel LN. Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol. 1990;131:815-825.
27. Persson I, Bergkvist L, Adami H-O. Reliability of women's histories of climacteric oestrogen treatment assessed by prescription forms. Int J Epidemiol. 1987;16:222-228,
28. Jain MG, Rohan TE, Howe GR. Agreement of self-reported use of menopausal hormone replacement therapy with physician reports. Epidemiology. 1999;10:260-263.
29. Steinberg KK, Smith SJ, Thacker SB, Stroup DF. Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology, 1994;5:415-421.
30. Colditz GA, Stampfer MJ, Willett WC, et al. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA. 1990;264:2648-2653.
31. Colditz GA, Stampfer MJ, Willett WC, et al. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control. 1992;3:433-439.